ISRCTN11633399进行中（未招募）未知
Biomarker Driven Antifungal Stewardship (BioDriveAFS) in acute leukaemia – a multi-centre randomised controlled trial to assess clinical and cost effectiveness
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 404
研究概览
简要总结
2024 Protocol article in https://pubmed.ncbi.nlm.nih.gov/38943201/ (added 01/07/2024)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 26/05/2023:
- •1. Aged =16 years
- •2. Diagnosis of new, or relapsed, acute leukaemia or haematological disorder judged to need intensive chemotherapy by the patient’s clinical care team. Eligible conditions include acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), high-risk myelodysplastic syndrome (HRMDS), or AML transformation of a myeloproliferative neoplasm (tMPN).
- •3. The patient is expected to have prolonged neutropenia related to intensive chemotherapy which would mandate either antifungal prophylaxis and/or systematic invasive fungal infection biomarker monitoring (at least weekly).
- •4. Patient is willing and able to give informed consent for participation in the study
- •Previous inclusion criteria:
- •1. Aged =16 years
- •2. New diagnosis of, or relapsed, acute myeloid leukaemia (AML; according to WHO classification), acute lymphoblastic leukaemia (ALL), or high-risk myelodysplasic syndrome (HRMDS) judged to need intensive chemotherapy by the patient’s clinical care team
- •3. The patient is expected to have prolonged neutropenia (=10 days) because of their intensive chemotherapy
- •4. Patient is willing and able to give informed consent for participation in the study
排除标准
- •Current exclusion criteria as of 24/04/2024:
- •1. Previous proven or probable invasive fungal infection (IFI) (according to the EORTC/MSG criteria). (I.e. this would not include previously treated cutaneous or other non-invasive infection, etc. If there is doubt about eligibility, please discuss with the local PI/research team and, if required, the central trial team / Chief Investigators).
- •2. Contraindication to all potential prophylactic antifungal agents (i.e. cannot be prescribed any recognised anti-Aspergillus agent as prophylaxis)
- •3. Planned chemotherapy using any regimen that mandates the use of systemic antifungal medication (i.e.Venetoclax-based regimens)
- •4. Received > 72 hours of systemic mould-acting antifungal prophylaxis or therapy, or biomarker monitoring for IFI, prior to trial enrolment
- •5. Commenced the first cycle of chemotherapy > 72 hours prior to trial enrolment
- •6. Current diagnosis of prolonged (> 72 hours) neutropenic fever
- •7. Pregnancy
- •Previous exclusion criteria as of 26/05/2023:
- •1. Previous proven or probable invasive fungal infection (IFI)
- •2. Contraindication to all potential prophylactic antifungal agents (i.e. cannot be prescribed any recognised anti-Aspergillus agent as prophylaxis)
- •3. Planned chemotherapy using any regimen that mandates the use of systemic antifungal medication (i.e.Venetoclax-based regimens)
- •4. Commenced antifungal prophylaxis or biomarker monitoring for IFI
- •5. Commenced the first cycle of chemotherapy AND has entered the invasive fungal infection (IFI) at risk period according to the usual local standard of care (i.e. the period that normally mandates local IFIpreventi on measures such as antifungal prophylaxis and/or biomarker monitoring)
- •6. Current diagnosis of neutropenic fever
- •7. Pregnancy
- •Previous exclusion criteria:
- •1. Previous proven or probable invasive fungal infection (IFI)
- •2. Contraindication to all potential prophylactic antifungal agents (i.e. cannot be prescribed any recognised anti-Aspergillus agent)
- •3. Current diagnosis of chemotherapy-related neutropenic fever
- •4. Pregnancy
- •5. Planned chemotherapy using a Venetoclax based regimen mandating posaconazole as a concurrent medication
研究者
相似试验
终止
不适用
New Biomarkers for Invasive Fungal Infections in Paediatric Haemato-oncologyHaemato-oncological Paediatric Patients Under Intensive ChemotherapyNCT02587377Queen Fabiola Children's University Hospital20
Unknown
不适用
fungalAi for Fungal Surveillance & Antifungal StewardshipFungal InfectionsNCT03793231Bayside Health1,000
进行中（未招募）
不适用
IBD-RESPONSE – predicting treatment response in Crohn’s disease and ulcerative colitisCrohn’s disease and ulcerative colitisDigestive SystemISRCTN96296121ewcastle upon Tyne Hospitals NHS Foundation Trust1,325
已完成
不适用
Rapid diagnostic tests and treatment opportunities for fungal infection in critically ill patientsCritically ill patients with suspected fungal infection or proven fungal infectionInfections and InfestationsCritically ill patients with suspected fungal infectionISRCTN43895480The Queen's University of Belfast1,251
已完成
不适用
Fungal Biomarkers to Reduce Duration of Empirical Antifungal Therapy: a Randomized Comparative Study (STAFE)Critical IllnessFungal InfectionNCT02154178University Hospital, Lille110